Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

Cessatech

19.12 DKK

-6.04 %

Less than 1K followers

CESSA

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
-6.04 %
-0.10 %
+19.80 %
+60.40 %
+71.33 %
+69.20 %
+1,034.72 %
+17.86 %
+77.29 %

Cessatech is a pivotal-stage paediatric biotech company developing first-in-class specialty hospital medicines for children, focused on high-impact unmet needs in acute and emergency care. The company focuses on specialty products designed for use in clinical settings and advances its programs through a partnership-based development model. Founded in 2020, Cessatech is headquartered in Denmark and led by a team with experience across drug development and commercialization.

Read more
Market cap
355.18M DKK
Turnover
1.11M DKK
Revenue
2.49M
EBIT %
-765.06 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
27.2
2026

Annual report '25

30.3
2026

General meeting '26

28.5
2026

Interim report Q1'26

All
Research
Press releases
ShowingAll content types
Regulatory press release2/2/2026, 7:00 AM

Cessatech: Welcome to the first quarter of 2026

Cessatech
Regulatory press release11/13/2025, 7:30 AM

Cessatech: Third Quarter Report Q3-2025

Cessatech
Regulatory press release10/31/2025, 12:00 PM

Cessatech: CT001 soon available for US hospitals in collaboration with STAQ Pharma, for acute pain management in children

Cessatech

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release8/21/2025, 6:30 AM

Cessatech: Second Quarter Report Q2-2025

Cessatech
Regulatory press release8/14/2025, 4:00 PM

Cessatech: The Marketing Authorisation Application (MAA) for CT001 is submitted to the European Medicines Agency (EMA) for acute pain management in children

Cessatech
Press release6/27/2025, 11:31 AM

Cessatech Q&A - June company presentation

Cessatech
Regulatory press release6/19/2025, 11:30 AM

Cessatech strengthens Executive Management with the promotion of Martin Juhl

Cessatech
Regulatory press release6/11/2025, 12:15 PM

Cessatech announce completion of the directed issue of shares

Cessatech
Regulatory press release5/28/2025, 8:30 PM

Cessatech has carried out a directed share issue of approximately DKK 14.8 million to strengthen its financial position ahead of U.S. commercial launch

Cessatech
Regulatory press release5/28/2025, 3:30 PM

Cessatech announces intention to carry out a directed share issue ahead of U.S. commercial launch

Cessatech
Regulatory press release5/28/2025, 3:15 PM

Cessatech announces positive top-line results from its final CT001 Study 0202

Cessatech
Regulatory press release5/15/2025, 6:30 AM

Cessatech: First Quarter Report Q1-2025

Cessatech
Regulatory press release4/30/2025, 1:45 PM

Cessatech announces that recruitment has completed in the Paediatric Study 0202, and now the EMA submission process can be initiated for CT001

Cessatech
Regulatory press release3/28/2025, 10:30 AM

Minutes from the Annual General Meeting in Cessatech A/S

Cessatech
Regulatory press release3/12/2025, 7:30 AM

Cessatech: Annual General Meeting - 28 March 2025

Cessatech
Regulatory press release2/28/2025, 7:30 AM

Cessatech A/S publishes Annual Report for the fiscal year 2024

Cessatech
Regulatory press release2/4/2025, 10:30 AM

Cessatech receives positive Notified Body opinion under MDR for CT001

Cessatech
Regulatory press release12/23/2024, 11:00 AM

Cessatech updates the milestones for the coming year

Cessatech
Regulatory press release11/13/2024, 12:00 PM

Cessatech: Third Quarter Report Q3-2024

Cessatech
Regulatory press release10/16/2024, 8:00 AM

Cessatech announces that recruitment has today reached the halfway point for patient recruitment with 75 included patients in the Paediatric Study 0202

Cessatech
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.